E-viri
Recenzirano
-
Jones, Martin R; Williamson, Laura M; Topham, James T; Lee, Michael K C; Goytain, Angela; Ho, Julie; Denroche, Robert E; Jang, GunHo; Pleasance, Erin; Shen, Yaoquing; Karasinska, Joanna M; McGhie, John P; Gill, Sharlene; Lim, Howard J; Moore, Malcolm J; Wong, Hui-Li; Ng, Tony; Yip, Stephen; Zhang, Wei; Sadeghi, Sara; Reisle, Carolyn; Mungall, Andrew J; Mungall, Karen L; Moore, Richard A; Ma, Yussanne; Knox, Jennifer J; Gallinger, Steven; Laskin, Janessa; Marra, Marco A; Schaeffer, David F; Jones, Steven J M; Renouf, Daniel J
Clinical cancer research, 2019-Aug-01, Letnik: 25, Številka: 15Journal Article
Gene fusions involving neuregulin 1 ( ) have been noted in multiple cancer types and have potential therapeutic implications. Although varying results have been reported in other cancer types, the efficacy of the HER-family kinase inhibitor afatinib in the treatment of fusion-positive pancreatic ductal adenocarcinoma is not fully understood. Forty-seven patients with pancreatic ductal adenocarcinoma received comprehensive whole-genome and transcriptome sequencing and analysis. Two patients with gene fusions involving received afatinib treatment, with response measured by pretreatment and posttreatment PET/CT imaging. Three of 47 (6%) patients with advanced pancreatic ductal adenocarcinoma were identified as wild type by whole-genome sequencing. All wild-type tumors were positive for gene fusions involving the ERBB3 ligand . Two of 3 patients with fusion-positive tumors were treated with afatinib and demonstrated a significant and rapid response while on therapy. This work adds to a growing body of evidence that gene fusions are recurrent, therapeutically actionable genomic events in pancreatic cancers. Based on the clinical outcomes described here, patients with wild-type tumors harboring gene fusions may benefit from treatment with afatinib. .
Avtor
![loading ... loading ...](themes/default/img/ajax-loading.gif)
Vnos na polico
Trajna povezava
- URL:
Faktor vpliva
Dostop do baze podatkov JCR je dovoljen samo uporabnikom iz Slovenije. Vaš trenutni IP-naslov ni na seznamu dovoljenih za dostop, zato je potrebna avtentikacija z ustreznim računom AAI.
Leto | Faktor vpliva | Izdaja | Kategorija | Razvrstitev | ||||
---|---|---|---|---|---|---|---|---|
JCR | SNIP | JCR | SNIP | JCR | SNIP | JCR | SNIP |
Baze podatkov, v katerih je revija indeksirana
Ime baze podatkov | Področje | Leto |
---|
Povezave do osebnih bibliografij avtorjev | Povezave do podatkov o raziskovalcih v sistemu SICRIS |
---|
Vir: Osebne bibliografije
in: SICRIS
To gradivo vam je dostopno v celotnem besedilu. Če kljub temu želite naročiti gradivo, kliknite gumb Nadaljuj.